Advertisement

β-Amyloid Imaging In Vivo and Its Possible Implications for Alzheimer’s Disease

  • N. P. L. G. Verhoeff
  • A. A. Wilson
  • H. F. Kung
  • D. Hussey
  • L. Trop
  • S. Houle
Chapter

Abstract

A central and initiating biochemical feature of most forms of Alzheimer’s disease (AD) is mis-processing of the neurotoxic amyloid β-peptide (Aβ). Promising therapeutic strategies are being developed directed at various steps in the Aβ biochemical cascade, resulting in reduction of accumulated Aβ. Promising radiotracers such as [18F]FDDNP, [11C]PIB and [11C]SB-13 have been developed for PET imaging of cerebral Aβ accumulation in vivo. The combination of these promising therapeutic strategies and radiotracers will hopefully allow for early detection and preventative treatment of AD. This will need to be studied prospectively in subjects at risk for AD, such as amnestic mild cognitive impairment (MCI), with adequate follow-up. Longitudinal Aβ PET studies may also help us resolve the question whether aging subjects without detectable cognitive impairment but with Aβ accumulation are at increased risk for developing AD. Repeated Aβ PET could be used to study the efficacy of β-amyloid-reducing medications.

Keywords

Positron Emission Tomography Single Photon Emission Compute Tomography Mild Cognitive Impairment Amnestic Mild Cognitive Impairment Amyloid Image 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agdeppa ED, Kepe V, Petri A, Satyamurthy N, Liu J, Huang SC, Small GW, Cole GM, Barrio JR (2003) In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[18F] fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. Neuroscience 117:723–730PubMedCrossRefGoogle Scholar
  2. Almkvist O, Basun H, Backman L, Herlitz A, Lannfelt L, Small B, Viitanen M, Wahlund LO, Win-blad B (1998) Mild cognitive impairment — an early stage of Alzheimer’s disease? J Neural Transm [Suppl] 54:21–29Google Scholar
  3. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The topographical and neu-roanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex 1:103–116PubMedCrossRefGoogle Scholar
  4. Bacskai BJ, Hyman BT (2002) Alzheimer’s disease: what multiphoton microscopy teaches us. Neuroscientist 8:386–390PubMedCrossRefGoogle Scholar
  5. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT (2002) Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab 22:1035–1041PubMedCrossRefGoogle Scholar
  6. Bornebroek M, Verzijlbergen JF, Haan J, Van Scheyen EJ, Verhoeff NPLG, Pauwels EK, Roos RA (1996) Potential for imaging cerebral amyloid deposits using 1231-labelled serum amyloid P component and SPET. Nucl Med Commun 17:929–933PubMedCrossRefGoogle Scholar
  7. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL (2001) Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 58:411–416PubMedCrossRefGoogle Scholar
  8. Braak H, Braak E (1990a) Neurofibrillary changes confined to the entorhinal region and an abundance of cortical amyloid in cases of presenile and senile dementia. Acta Neuropathol (Berl) 80:479–486CrossRefGoogle Scholar
  9. Braak H, Braak E (1990b) Alzheimer’s disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 49:215–224PubMedCrossRefGoogle Scholar
  10. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239–259CrossRefGoogle Scholar
  11. Braak H, Braak E, Bohl J, Lang W (1989) Alzheimer’s disease: amyloid plaques in the cerebellum. J Neurol Sci 93:277–287PubMedCrossRefGoogle Scholar
  12. Brilliant MJ, Elble RJ, Ghobrial M, Struble RG (1997) The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer’s disease. Neuropathol Appl Neurobiol 23:322–325CrossRefGoogle Scholar
  13. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, Westaway D (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276:21562–21570PubMedCrossRefGoogle Scholar
  14. Cummings BJ, Cotman CW (1995) Image analysis of beta-amyloid load in Alzheimer’s disease and relation to dementia severity. Lancet 346:1524–1528PubMedCrossRefGoogle Scholar
  15. DeCarli C (2003) Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2:15–21PubMedCrossRefGoogle Scholar
  16. Dewachter I, Van Leuven F (2002) Secretases as targets for the treatment of Alzheimer’s disease: the prospects. Lancet Neurol 1:409–416PubMedCrossRefGoogle Scholar
  17. Duyckaerts C, Delaere P, Poulain V, Brion JP, Hauw JJ (1988) Does amyloid precede paired helical filaments in the senile plaque? A study of 15 cases with graded intellectual status in aging and Alzheimer disease. Neurosci Lett 91:354–359PubMedCrossRefGoogle Scholar
  18. Engler H, Blomqvist G, Bergström M, Estrada S, Sandell J, Antoni G, Langström B (2002) First human study with a benzothiazole amyloid-imaging agent in Alzheimer’s disease and control subjects. Neurobiol Aging 23:S429Google Scholar
  19. Friedland RP, Kalaria R, Berridge M, Miraldi F, Hedera P, Reno J, Lyle L, Marotta CA (1997) Neuroimaging of vessel amyloid in Alzheimer’s disease. Ann N Y Acad Sci 826:242–247CrossRefGoogle Scholar
  20. Hansen LA, Masliah E, Galasko D, Terry RD (1993) Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 52:648–654PubMedCrossRefGoogle Scholar
  21. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356PubMedCrossRefGoogle Scholar
  22. Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW (2000) Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging 21:89–96PubMedCrossRefGoogle Scholar
  23. Head E, Milgram NW, Cotman CW (2001) Neurobiological models of aging in the dog and other vertebrate species. In: Hof PR, Mobbs CV (eds) Functional neurobiology of aging. Academic, New York, pp 457–470CrossRefGoogle Scholar
  24. Janus C, Chishti MA, Westaway D (2000) Transgenic mouse models of Alzheimer’s disease. Biochim Biophys Acta 1502:63–75PubMedCrossRefGoogle Scholar
  25. Joachim CL, Morris JH, Selkoe DJ (1989) Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol 135:309–319PubMedGoogle Scholar
  26. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, Hamilton RL, Ikonomovic MD, De-Kosky ST, Mathis CA (2003) The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23:2086–2092PubMedGoogle Scholar
  27. Kung MP, Skovronsky DM, Hou C, Zhuang ZP, Gur TL, Zhang B, Trojanowski JQ, Lee VM, Kung HF (2003) Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer’s patients. Mol Neurosci 20:15–24CrossRefGoogle Scholar
  28. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I (2002) Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156:445–453PubMedCrossRefGoogle Scholar
  29. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740–2754PubMedCrossRefGoogle Scholar
  30. Matsuda H (2001) Cerebral blood flow and metabolic abnormalities in Alzheimer’s disease. Ann Nucl Med 15:85–92PubMedCrossRefGoogle Scholar
  31. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMedCrossRefGoogle Scholar
  32. Morris JC, Price JL (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J Mol Neurosci 17:101–118PubMedCrossRefGoogle Scholar
  33. Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, Berg L (1996) Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology 46:707–719PubMedCrossRefGoogle Scholar
  34. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58:397–405PubMedCrossRefGoogle Scholar
  35. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH (1999) Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol 158:469–490PubMedCrossRefGoogle Scholar
  36. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001a) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992PubMedCrossRefGoogle Scholar
  37. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001b) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1133–1142PubMedCrossRefGoogle Scholar
  38. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ, Jack CR Jr (2002) Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 11:315–329PubMedCrossRefGoogle Scholar
  39. Price DL, Martin LJ, Sisodia SS, Wagster MV, Koo EH, Walker LC, Koliatsos VE, Cork LC (1991) Aged non-human primates: an animal model of age-associated neurodegenerative disease. Brain Pathol 1:287–296PubMedCrossRefGoogle Scholar
  40. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358–368PubMedCrossRefGoogle Scholar
  41. Redwine JM, Kosofsky B, Jacobs RE, Games D, Reilly JF, Morrison JH, Young WG, Bloom FE (2003) Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci USA 100:1381–1386PubMedCrossRefGoogle Scholar
  42. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59:1729–1734PubMedCrossRefGoogle Scholar
  43. Scheltens P, Fox N, Barkhof F, De Carli C (2002) Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 1:13–21PubMedCrossRefGoogle Scholar
  44. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10:24–35PubMedGoogle Scholar
  45. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286:2120–2127PubMedCrossRefGoogle Scholar
  46. Small GW, Agdeppa ED, Kepe V, Satyamurthy N, Huang SC, Barrio JR (2002) In vivo brain imaging of tangle burden in humans. J Mol Neurosci 19:323–327PubMedGoogle Scholar
  47. Suenaga T, Hirano A, Llena JF, Yen SH, Dickson DW (1990a) Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer’s disease. Acta Neuropathol (Berl) 80:280–286CrossRefGoogle Scholar
  48. Suenaga T, Hirano A, Llena JF, Ksiezak-Reding H, Yen SH, Dickson DW (1990b) Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer’s disease. J Neuropathol Exp Neurol 49:31–40PubMedCrossRefGoogle Scholar
  49. Terry RD, Hansen LA, DeTeresa R, Davies P, Tobias H, Katzman R(1987) Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J Neuropathol Exp Neurol 46:262–268PubMedCrossRefGoogle Scholar
  50. Thai DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800CrossRefGoogle Scholar
  51. Thompson SA, Hodges JR (2002) Mild cognitive impairment: a clinically useful but currently ill-defined concept? Neurocase 8:405–410PubMedCrossRefGoogle Scholar
  52. Troncoso JC, Martin LJ, Dal Forno G, Kawas CH (1996) Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 17:365–371PubMedCrossRefGoogle Scholar
  53. Troncoso JC, Cataldo AM, Nixon RA, Barnett JL, Lee MK, Checler F, Fowler DR, Smialek JE, Crain B, Martin LJ, Kawas CH (1998) Neuropathology of preclinical and clinical late-onset Alzheimer’s disease. Ann Neurol 43:673–676PubMedCrossRefGoogle Scholar
  54. Verhoeff NPLG (2002) Pharmacotherapy of agitation and psychotic symptoms in Alzheimer’s disease. Expert Rev Neurotherapeut 2:655–664CrossRefGoogle Scholar
  55. Verhoeff NPLG (2003) Do NSAIDs reduce the risk of developing AD? CAGP Bull 10:14–15Google Scholar
  56. Verhoeff NPLG, Wilson AA, Nobrega J, Milgram NW, Westaway D, Head E, Hussey D, Tapp D, Trop L, Giuliano F, Araujo J, Ginovart N, Richardson L, Singh K, Houle S (2003) Development of positron emission tomography (PET) tracers for beta-amyloid imaging in vivo. J Cereb Blood Flow Metab 23[Suppl 1]:685Google Scholar
  57. Visser PJ, Verhey FRJ, Jolles J, Jonker C (2002) Course of minimal dementia and predictors of outcome. Int J Geriatr Psychiatry 17:835–841CrossRefGoogle Scholar
  58. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH (2003) Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 50:293–302PubMedCrossRefGoogle Scholar
  59. Wang Y, Klunk WE, Huang GF, Debnath ML, Holt DP, Mathis CA (2002) Synthesis and evaluation of 2-(3′-iodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer’s disease. J Mol Neurosci 19:11–16PubMedCrossRefGoogle Scholar
  60. Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS (1999) Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis Assoc Disord 13:226–231PubMedCrossRefGoogle Scholar
  61. Wolfe MS (2001) Secretase targets for Alzheimer’s disease: identification and therapeutic potential. J Med Chem 44:2039–2060PubMedCrossRefGoogle Scholar
  62. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y (1989) Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol (Berl) 77:314–319CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • N. P. L. G. Verhoeff
    • 1
  • A. A. Wilson
    • 2
  • H. F. Kung
    • 3
  • D. Hussey
    • 2
  • L. Trop
    • 1
  • S. Houle
  1. 1.Kunin-Lunefeld Applied Research Centre, Baycrest Centre for Geriatric Care and Pet Centre, Center for Addiction and Mental Health and Department of PsychiatryUniversity of TorontoTorontoCanada
  2. 2.PET Centre, Centre for Addiction and Mental Health and Department of PsychiatryUniversity of TorontoTorontoCanada
  3. 3.Department of RadiologyUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations